3Q FY3/2018 Supplementary Material

1.Financial Highlights

2013/3	2014/3	2015/3	2016/3	2017/3
139,466	165,347	181,844	219,239	223,468
7.2%	18.6%	10.0%	20.6%	1.9%
3,245	4,744	6,647	10,489	8,519
2.3%	2.9%	3.7%	4.8%	3.8%
184	1,901	2,778	6,329	4,638
0.1%	1.2%	1.5%	2.9%	2.1%
14,702	15,849	17,635	32,473	36,447
15.5%	13.5%	13.6%	20.6%	20.4%
	139,466 7.2% 3,245 2.3% 184 0.1% 14,702	139,466 165,347 7.2% 18.6% 3,245 4,744 2.3% 2.9% 184 1,901 0.1% 1.2% 14,702 15,849	139,466 165,347 181,844 7.2% 18.6% 10.0% 3,245 4,744 6,647 2.3% 2.9% 3.7% 184 1,901 2,778 0.1% 1.2% 1.5% 14,702 15,849 17,635	139,466 165,347 181,844 219,239 7.2% 18.6% 10.0% 20.6% 3,245 4,744 6,647 10,489 2.3% 2.9% 3.7% 4.8% 184 1,901 2,778 6,329 0.1% 1.2% 1.5% 2.9% 14,702 15,849 17,635 32,473

	2014/3 3Q	2015/3 3Q	2016/3 3Q	2017/3 3Q	2018/3 3Q
Net sales (Millions of yen)	123,077	134,386	158,645	166,051	180,250
YoY growth rate	18.8%	9.2%	18.1%	4.7%	8.6%
Operating profit (Millions of yen)	3,646	4,615	7,353	6,101	8,328
Operating margin	3.0%	3.4%	4.6%	3.7%	4.6%
Profit attributable to owners of parent (Millions of yen)	1,631	2,245	4,305	3,307	5,015
Return on sales	1.3%	1.7%	2.7%	2.0%	2.8%
Shareholder's equity (Millions of yen)	15,728	17,004	30,682	35,104	40,419
Equity ratio	13.4%	13.0%	19.4%	20.6%	21.5%

2.Dispensing Pharmacy Business

	2013/3	2014/3	2015/3	2016/3	2017/3
No.of pharmacies opened	59	37	29	27	42
Including M&A	0	4	1	5	21
No.of pharmacies at the end of each period	466	494	511	527	557
Net sales of dispenshing pharmacy business (Millions of yen)	131,052	145,957	157,999	190,874	189,327
Sales per Pharmacy (Millions of yen)	296	304	314	367	349
No.of prescription (thousands)	10,482	11,090	11,695	12,301	12,949
Unit prices of prescription (yen)	12,295	12,954	13,330	15,297	14,382

	2014/3 3Q	2015/3 3Q	2016/3 3Q	2017/3 3Q	2018/3 3Q
No.of pharmacies opened	30	22	23	34	28
Including M&A	4	0	4	18	8
No.of pharmacies at the end of each period	489	509	524	553	580
Net sales of dispenshing pharmacy business (Millions of yen)	108,575	116,822	137,850	140,758	152,799
Sales per Pharmacy(Millions of yen)	224	232	266	259	267
No.of prescription(thousands)	8,306	8,736	9,162	9,667	10,256
Unit prices of prescription (yen)	12,871	13,188	14,879	14,386	14,701

3.Consolidated Balance Sheet

						(Mi	illions of yen)
	(As of the end of the period)	2013/3 3Q	2014/3 3Q	2015/3 3Q	2016/3 3Q	2017/3 3Q	2018/3 3Q
Assets							
Current assets							,
Cash and deposits		12,006	17,016	15,561	32,538	17,687	19,877
Notes receivable-trade		_	715	709	181	349	326
Accounts receivable-trade		14,262	18,136	20,244	25,165	26,262	28,019
Electronically recorded monetary	claims-operating	_	_	865	1,161	1,584	1,251
Merchandise and finished goods		12,826	14,147	17,858	18,063	22,812	25,095
Work in process		144	852	951	1,417	2,014	1,841
Raw materials and supplies		345	3,226	3,562	4,669	5,662	5,970
Other		1,992	2,614	3,235	3,421	3,474	3,104
Allowance for doubtful accounts		(9)	(8)	(9)	(13)	(12)	(6)
Total current assets		41,568	56,699	62,979	86,604	79,836	85,480
Non-current assets							ľ
Property, plant and equipment							ľ
Buildings and structures, net		12,924	13,792	18,272	21,773	22,510	22,515
Land		13,207	15,271	15,556	17,143	17,966	18,134
Construction in progress		925	4,140	5,099	1,669	9,707	18,476
Other, net		5,526	6,202	7,760	9,830	13,181	15,310
Total property, plant and equipn	nent	32,583	39,406	46,689	50,416	63,366	74,437
Intangible assets							ŀ
Goodwill		7,843	8,974	8,764	8,626	14,318	15,484
Other		1,740	1,732	1,735	1,615	2,176	2,379
Total intangible assets		9,584	10,706	10,499	10,241	16,495	17,863
Investments and other assets							
Investment securities		1,002	926	1,076	1,211	1,073	20
Lease and guarantee deposits		6,780	6,954	7,029	6,985	7,105	7,044
Other		2,208	2,982	2,575	2,695	2,749	2,756
Total investments and other asse	ets	9,990	10,863	10,682	10,892	10,928	9,820
Total non-current assets		52,158	60,976	67,871	71,550	90,790	102,121
Total assets		93,727	117,676	130,850	158,155	170,626	187,601
	-						-

		004440.05	2015/205	00101000		illions of yen)
(As of the end of the per	iod) 2013/3 3Q	2014/3 3Q	2015/3 3Q	2016/3 3Q	2017/3 3Q	2018/3 3Q
Liabilities						
Current liabilities						
Notes payable-trade	_	2,466	1,112	_	_	_
Accounts payable-trade	25,503	30,008	35,019	44,239	42,275	44,319
Electronically recorded obligations-operating	_	_	1,996	2,168	2,543	2,434
Short-term loans payable	2,800	5,550	2,550	1,210	5,600	_
Current portion of bonds	_	7,092	_	7,000	_	_
Current portion of long-term loans payable	12,401	3,589	5,572	5,988	12,442	15,998
Income taxes payable	1,351	582	456	1,287	316	1,367
Provision for bonuses	803	889	1,033	1,114	1,276	1,352
Provision for directors' bonuses	_	5	_	_	_	_
Provision for sales rebates	222	229	136	134	_	_
Other	3,281	4,670	5,828	6,900	7,620	8,101
Total current liabilities	46,364	55,086	53,705	70,043	72,074	73,574
Non-current liabilities						
Bonds payable	14,000	7,000	7,000	_	_	_
Long-term loans payable	17,650	34,312	47,361	51,873	58,358	68,963
Provision for retirement benefits	239	511	· —	· <u> </u>	· <u> </u>	· —
Provision for directors' retirement benefits	662	1,257	864	933	924	1,022
Net defined benefit liability	_	_	631	1,027	1,285	1,450
Other	861	1,729	4,284	3,594	2,878	2,170
Total non-current liabilities	33,413	44,811	60,141	57,428	63,446	73,607
Total liabilities	79,777	99,898	113,846	127,472	135,521	147,181
Net assets	,	,	,	,	,	, , , , , , , , , , , , , , , , , , , ,
Shareholders' equity						
Capital stock	3,953	3,953	3,953	3,953	3,953	3,953
Capital surplus	4,754	4,754	4,754	10,926	10,926	10,926
Retained earnings	7,308	9,039	11,335	15,647	20,166	25,727
Treasury shares	(2,288)		(3,107)	(44)	(45)	(47)
Total shareholders' equity	13,727	15,558	16,934	30,483	35,000	40,560
Accumulated other comprehensive income	,	,	10,001	33, 133	33,333	10,000
Valuation difference on available-for-sale securities	222	170	267	372	285	0
Remeasurements of defined benefit plans		.70	(197)	(173)	(181)	(140)
Total accumulated other comprehensive income	222	170	69	199	103	(140)
Minority interests	222	2,049	09	199	103	(140)
		2,049				

17,778

117,676

17,004

130,850

30,682

158,155

13,949

93,727

Total net assets

Total liabilities and net assets

40,419

187,601

35,104

170,626

4. Consolidated Statement of Income

(Millions of yen) (For the Nine-month Period) 2013/3 3Q 2014/3 3Q 2015/3 3Q 2016/3 3Q 2017/3 3Q 2018/3 3Q Net sales 103,596 123,077 134,386 158,645 166,051 180,250 Cost of sales 87,752 103,941 111,065 130,386 137,190 147,146 Gross profit 19,135 15,843 23,320 28,259 28,860 33,103 Selling, general and administrative expenses 13,803 15.489 18,705 20,905 22,759 24,775 Operating profit 2,039 3,646 4,615 7,353 6,101 8,328 Non-operating income Commission fee 86 90 101 106 113 Rent income 107 56 245 283 300 324 Insurance return 74 Other 252 186 172 132 131 153 Total non-operating income 308 380 508 517 613 590 Non-operating expenses Interest expenses 440 531 611 600 524 487 Commission fee 23 50 23 18 13 22 Rent expenses 213 240 244 Other 251 210 388 148 163 176 Total non-operating expenses 715 792 930 1,023 981 941 Ordinary profit 1,632 3,234 4,100 6.889 5,773 7.988 Extraordinary income Gain on sales of non-current assets 17 22 6 5 3 0 Gain on sales of investment securities 1 360 Gain on transfer of business 38 Total extraordinary income 6 19 5 22 3 398 Extraordinary losses Impairment loss 228 112 47 99 57 173 Loss on sales of non-current assets O 6 10 Loss on sales of investment securities 0 Total extraordinary losses 228 113 47 99 63 183 Profit before income taxes 1,410 3,139 4,058 6,812 5,713 8,203 Income taxes-current 707 1,252 1,291 2,213 1,787 2,860 Income taxes for prior periods 1,034 Income taxes-deferred 291 521 617 327 90 293 Total income taxes 1,831 1,544 1,812 2,506 2,405 3,187 Profit attributable to non-controlling interests note1 (35)Profit attributable to owners of parent note2 (421)1,631 2,245 4,305 3,307 5,015

Note1 : From the 2016/3 1Q, the presentation of "Minority interests" was changed to "Profit attributable to non-controlling interests."

Note2 : From the 2016/3 1Q, the presentation of "NET Income" was changed to "Profit attributable to owners of parent."

5.Business Segment Performance

					(M ²	lillions of yen)
	2013/3 3Q	2014/3 3Q	2015/3 3Q	2016/3 3Q	2017/3 3Q	2018/3 3Q
Dispensing pharmacy business						
Net sales	97,521	108,575	116,822	137,850	140,758	152,799
Segment profit	4,679	5,791	5,419	7,147	6,699	9,050
Pharmaceutical manufacturing and sales business				-	-	
Net sales	8,232	17,275	20,603	24,354	27,634	29,300
Segment profit	212	427	1,447	2,201	1,410	1,431
Medical Professional Staffing and Placement Business						
Net sales	2,965	3,763	4,684	6,419	7,675	8,948
Segment profit	382	602	895	1,127	1,225	1,416

6.Company Plofile

Trade Name

Established	March 1980
Headquarters	37F GranTokyo North Tower,1-9-1,Marunouchi,Chiyoda-Ku,100-6737 Tokyo
Capital	3,953.02 million yen
Total Number of Issued Shares	16,024,000 shares
Fiscal Year-end	March
Stock Exchange for Listing	Tokyo Stock Exchange(TSE) First Section
Securities Code	3341
Our Business	Management of health insurance dispensing chain pharmacies,
	manufacture and sales of generic drugs,
	employment placement and dispatching service of medical professionals,
	information provision and consulting
Number of pharmacies(As of December 31,2017)	580

NIHON CHOUZAI Co.,Ltd.